A. SYNTHESIS OF NEUTRON CAPTURE THERAPY AGENTS

Carbo!'anyl precursors
Carboranes contain ten boron atoms in a three-dimensional space equivalent to a benzene ring; consequently, the carborane isomers can be utilized to prepare a variety of boron-rich agents , for potential use in boron-neutron-capture therapy.
[Wh_reO '-BH, B==CH] We are currently developing synthetic methodology suitable for preparing amino acids and other physiologically active compounds of potential use in BNCT. 
_-4
Gadolinium NOT Agents
We have synthesized and carried out biodistribution studies of gadolinium labeled liposomes (GLL) which were developed in our laboratory. Gadolinium (like boron-10) has an excellent neutron cross section and is considered to be of potential use in neutron capture therapy. GLL are con,, _,ructedby adding gadolinium based amphiphiles, such as the one illustrated on the = next page, to liposome preparations. [See Section Ilia, articles 4, 5, 7, 8 and 9; Section IIIb, abstracts 2, 4, 7, 9] ', . 
Figure:
In Vivo measurement of boron-11 transverse relaxation : ('1"2) in the rat.
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To overcome problems due to the short T2 of boron-11, we designed a back-projection technique from which we were able to generate the world's first boron-11 MRI image of a rat that had been infused with a BNCT agent. The spectra were acquired in the presence of variably orientated gradients and these spectra were used as input for reconstructing filtered back-projection images such as the one shown below. Though successful, back-projection boron-41MRI istime consumingand provides onlymodestspatial resolution. We then developed an alternate imaging method for nuclei with very short T2 relaxation times. As in backprojection, the technique utilizes the FID, rather than the echo signal, but involves only phase-encoding of the signal without frequency encoding, The method was tested by obtaining boron-11 images of aqueous boron phantoms, and was used to map the boron-11 distribution in an intact Fischer 344 rat infused with a therapeutic dose of dimeric sulfhydryl dodecaborane agent by our colleagues (Slatkin and Micca) at Brookhaven National Laboratory.
In the new method both spatial dimensions are phase-encoded by the usual amplitude cycling of gradients along the corresponding directions. The time during which these gradients are phase-encoding the signal is extremely short, 200/_s. The time-domain signal is then Fourier transformed, in the usual manner, to yield an x-y image. An extension to three spatial dimensions can be achieved by adding a third phase-encoding gradient along the z-axis.
The minimal performance time of the proposed sequence is longer than that of a conventional spin-warp sequence since at {east one -_ scan for each resolution element is required. But this is not an obstacle for the imaging of boron-11 in-vivo since the necessary number of scans Maruyama,and L. Huang, "Gadolinium-LabeledLiposomes
ContainingVariousAmphiphilicGd-DTPA Derivativesof Varying
Chain Length: Targeted MRI Enhancement Agents", Magn.
Reson. Med., 9, 373 (1991). 
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VII. PRESENT STATE OF KNOWLEDGE
Boron neutron capture therapy is a form of brachyoradlotherapy which is based on the properties of boron-10 and the reaction which occurs when it is exposed to neutrons. Thus successful BNCT is dependent on two factors: (1)
• effective delivery of a sufficient quantity of boron-10 to the targeted lesion and (2) neutron flux of sufficient energy to achieve the prerequisitenuclear reaction while minimizing damage to healthy tissue.
Significant advances have been made in both these areas in recent years by chemists and physicists such that the future of BNCT in medicine appears assured, but much remains to be accomplished before BNCT is a clinical reality. 
